GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)

GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 1.61 trillion. The enterprise value is 1.66 trillion.

Market Cap	1.61T
Enterprise Value	1.66T

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 42.37 million shares outstanding. The number of shares has increased by 2.70% in one year.

Current Share Class	42.37M
Shares Outstanding	42.37M
Shares Change (YoY)	+2.70%
Shares Change (QoQ)	+1.79%
Owned by Insiders (%)	2.41%
Owned by Institutions (%)	4.56%
Float	30.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.86
PB Ratio	32.01
P/TBV Ratio	33.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-27.81
EV / Sales	22.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-90.73

Financial Position

The company has a current ratio of 0.51, with a Debt / Equity ratio of 1.40.

Current Ratio	0.51
Quick Ratio	0.37
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-3.85
Interest Coverage	-1.92

Financial Efficiency

Return on equity (ROE) is -95.34% and return on invested capital (ROIC) is -6.27%.

Return on Equity (ROE)	-95.34%
Return on Assets (ROA)	-5.01%
Return on Invested Capital (ROIC)	-6.27%
Return on Capital Employed (ROCE)	-13.93%
Weighted Average Cost of Capital (WACC)	11.46%
Revenue Per Employee	404.62M
Profits Per Employee	-328.11M
Employee Count	182
Asset Turnover	0.49
Inventory Turnover	5.40

Taxes

Income Tax	-670.13M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +76.33% in the last 52 weeks. The beta is 1.35, so GemVax&KAEL's price volatility has been higher than the market average.

Beta (5Y)	1.35
52-Week Price Change	+76.33%
50-Day Moving Average	30,873.00
200-Day Moving Average	44,730.75
Relative Strength Index (RSI)	55.87
Average Volume (20 Days)	521,711

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 73.64 billion and -59.72 billion in losses. Loss per share was -1,470.58.

Revenue	73.64B
Gross Profit	25.74B
Operating Income	-12.10B
Pretax Income	-60.39B
Net Income	-59.72B
EBITDA	-7.71B
EBIT	-12.10B
Loss Per Share	-1,470.58

Balance Sheet

The company has 19.72 billion in cash and 70.40 billion in debt, with a net cash position of -50.68 billion or -1,196.22 per share.

Cash & Cash Equivalents	19.72B
Total Debt	70.40B
Net Cash	-50.68B
Net Cash Per Share	-1,196.22
Equity (Book Value)	50.30B
Book Value Per Share	1,195.46
Working Capital	-35.02B

Cash Flow

In the last 12 months, operating cash flow was -16.24 billion and capital expenditures -2.06 billion, giving a free cash flow of -18.30 billion.

Operating Cash Flow	-16.24B
Capital Expenditures	-2.06B
Free Cash Flow	-18.30B
FCF Per Share	-432.00

Margins

Gross margin is 34.95%, with operating and profit margins of -16.44% and -81.09%.

Gross Margin	34.95%
Operating Margin	-16.44%
Pretax Margin	-82.00%
Profit Margin	-81.09%
EBITDA Margin	-10.47%
EBIT Margin	-16.44%
FCF Margin	n/a

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.70%
Shareholder Yield	-2.70%
Earnings Yield	-3.71%
FCF Yield	-1.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 7.45 and a Piotroski F-Score of 4.

Altman Z-Score	7.45
Piotroski F-Score	4